TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8355313
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with anti-pseudomonal third-generation cephalosporin (cefoperazone or ceftazidime)
Study: 8355313
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with anti-pseudomonal third-generation cephalosporin (cefoperazone or ceftazidime) plus gentamicin
Study: 2834488
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (CY 222)
Study: 20698989
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT), treated 3 times per week for 12 weeks
Study: 16647994
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (0.2 mg/kg body weight)
Study: 16647994
Drug: Rectal diazepam
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diazepam (0.3 mg/kg body weight)
Study: 1483156
Drug: Epinephrine injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine injection (unconditioned stimulus) for three or four days
Study: 2255262
Drug: Calcium pidolate
Normalized name: calcium pidolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium pidolate (1 g elemental calcium)
Study: 19243424
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate 800 mg
Study: 11795850
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with FO (1 g EPA + DHA daily)
Study: 11795850
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with ALNA (2 g daily)
Study: 11026996
Drug: Oral sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulfasalazine (group 1)
Study: 8892775
Drug: Bunazosin (alpha-blocker)
Normalized name: bunazosin
DrugBank: Bunazosin (DB12230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin (alpha-blocker)
Study: 6342407
Drug: Orthokeratology (OK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthokeratology (OK) treatment group
Study: 2783678
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol
Study: 22679525
Drug: Nitazoxanide (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (1,000 mg)
Study: 19849767
Drug: AMC/DCBA throat
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMC/DCBA throat lozenges (n = 155)
Study: 2187445
Drug: Single-dose prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose prophylaxis with cefotiam and metronidazol
Study: 31385333
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral health education (CE)
Study: 21297191
Drug: 2‐year twice‐weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐year twice‐weekly weight training intervention
Study: 20058059
Drug: Delayed Treatment
Normalized name: GRANULES, DELAYED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Treatment Control (DTC)
Study: 19070356
Drug: Leukotriene receptor
Normalized name: Leukotriene receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene receptor antagonist
Study: 7102584
Drug: equicaloric amount
Approvals — FDA: no, EMA: no, PMDA: no
Description: equicaloric amount of glucose solution
Study: 7102584
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of water
Study: 26020673
Drug: Protocol-based fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol-based fluid boluses (15 mL/kg)
Study: 18469279
Drug: Lutein (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (12 mg/d)
Study: 18469279
Drug: DHA (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (800 mg/d)
Study: 23716765
Drug: Granisetron 1
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 1 mg
Study: 11299816
Drug: SK-1 administered
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK-1 administered intravenously at dosages of 2, 4, or 10 mg three times.
Study: 9165140
Drug: Megestrol acetate,
Normalized name: megestrol acetate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megestrol acetate, 40 mg qid
Study: 9165140
Drug: Cisapride, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride, 5 mg tid
Study: 24286226
Drug: On-demand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand therapy for 16 weeks
Study: 24286226
Drug: Prophylactic regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic regimen nonacog alfa 100 IU kg(‐1) once weekly
Study: 24286226
Drug: Prophylactic regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic regimen nonacog alfa 50 IU kg(‐1) twice weekly
Study: 18703328
Drug: Pari Boy
Normalized name: Paris quadrifolia extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pari Boy device with 2.0 micromol/L capsaicin
Study: 18703328
Drug: Maxin MA3
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxin MA3 device with 0.06 micromol/L capsaicin
Study: 18703328
Drug: Maxin MA3
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxin MA3 device with 0.3 micromol/L capsaicin
Study: 12796769
Drug: Enalapril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (mean dosage 14.6 mg, max 20 mg)
Study: 10980076
Drug: Peer review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer review meetings with feedback on prescribing behaviour for asthma treatment.
Study: 1391262
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of natural porcine surfactant (Curosurf)
Study: 3755640
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg X kg‐1
Study: 3755640
Drug: Succinylcholine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.0 mg X kg‐1
Study: 3755640
Drug: Atracurium 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.75 mg X kg‐1
Study: 19520905
Drug: Low-dose spiral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spiral computed tomography (LDCT)
Study: 2662130
Drug: Terbutaline, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline, 5 mg
Study: 2662130
Drug: Theophylline, 200
Normalized name: Theophylline, 200 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline, 200 mg
Study: 31476413
Drug: Salmonella Typhi
Normalized name: Salmonella Typhi Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmonella Typhi vaccination (0.025 mg; Typhim Vi, Sanofi Pasteur, UK)
Study: 27527240
Drug: Amitriptyline (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25, 50, 100 mg once daily at night for 1 week)
Study: 23098325
Drug: Fluticasone/formoterol 250/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/formoterol 250/10 μg
Study: 23098325
Drug: Fluticasone/formoterol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/formoterol (both doses)
Study: 19797133
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antibiotic discontinuation strategy according to guidelines)
Study: 22372513
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) initiated at 30 mg, titrated in 20 mg increments to a maximum of 70 mg over 4-5 weeks.
Study: 27534056
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic therapy and Wobenzym
Study: 12803576
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of plain-formulated aspirin (PFASA)
Study: 1800302
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg tid for 4 weeks
Study: 31504399
Drug: Low-dose rivaroxaban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rivaroxaban added to aspirin
Study: 19249425
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (control)
Study: 18597599
Drug: Amine fluoride/stannous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amine fluoride/stannous fluoride (ASF) mouthrinse at 10 ml (ASF-10)
Study: 18597599
Drug: Amine fluoride/stannous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amine fluoride/stannous fluoride (ASF) mouthrinse at 20 ml (ASF-20)
Study: 16267959
Drug: Amodiaquine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (30 mg/kg over three days, 10 mg/kg/day)
Study: 16267959
Drug: Chloroquine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (30 mg/kg over three days, 10 mg/kg/day)
Study: 12427293
Drug: Medication-free trial
Normalized name: benzoyl peroxide Medicated Pad [Triaz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-free trial after SSRI treatment
Study: 12427293
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of SSRI treatment
Study: 9457946
Drug: Washing, swim-down,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Washing, swim-down, refrigeration/heparin techniques
Study: 7699828
Drug: Patient-Controlled Sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-Controlled Sedation (PCS) - 1.5 mg bolus dose of midazolam
Study: 23475568
Drug: Metformin (IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (IR and XR formulations)
Study: 17275226
Drug: Black cohosh
Normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black cohosh (160 mg daily)
Study: 17275226
Drug: Multibotanical including
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Multibotanical including black cohosh (200 mg daily)
Study: 17275226
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen .625 mg, with or without medroxyprogesterone acetate 2.5mg daily
Study: 11681821
Drug: Multivitamins with
Normalized name: MULTIVITAMINS WITH MINERALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamins with iron (MV with iron) administered daily for 3 months
Study: 11681821
Drug: Noniron multivitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noniron multivitamins (MV without iron) administered daily for 3 months
Study: 9226158
Drug: G-CSF (filgrastim)
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (filgrastim) 5 microg/kg/d subcutaneously
Study: 11751732
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg sublingual nitroglycerin (NTG)
Study: 3686222
Drug: Control (Diagnostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Diagnostic discography without enzyme injection)
Study: 28930874
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of fish oil daily for 21 days
Study: 22250190
Drug: 50‐mL roll‐on
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50‐mL roll‐on dispenser
Study: 16061828
Drug: Thyroxine suppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine suppressive treatment
Study: 10879311
Drug: Triple-antibiotic ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-antibiotic ointment (polymyxin B-bacitracin-neomycin), applied twice daily for up to 14 days
Study: 10879311
Drug: Simple gauze-type
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple gauze-type dressing, applied twice daily for up to 14 days
Study: 8636300
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (100 mg, im, weekly) plus levonorgestrel (500 micrograms, orally, daily)
Study: 1466089
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei preparation (BLP), 3 g/day
Study: 29872280
Drug: Home-based program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based program + weekly class-style session (CS group, n=251)
Study: 21178594
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg intravenous infusion)
Study: 18450870
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation plus oral rehydration salts
Study: 18450870
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration salts alone (Control)
Study: 7583751
Drug: Multimedia campaign
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimedia campaign regarding alcohol and other drug abuse
Study: 2517626
Drug: 41% BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 41% BCAA solution
Study: 2517626
Drug: 23% BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23% BCAA solution
Study: 605356
Drug: 1-hyoscyamine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hyoscyamine (0.8 mg)
Study: 27418685
Drug: PAH drug
Normalized name: PAH
DrugBank: Aminohippuric acid (DB00345)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAH drug treatment in inoperable CTEPH
Study: 27418685
Drug: PAH drug
Normalized name: PAH
DrugBank: Aminohippuric acid (DB00345)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAH drug treatment in operable CTEPH
Study: 8941409
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2) and paclitaxel (135 mg/m2)
Study: 8941409
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2) and cyclophosphamide (750 mg/m2)
Study: 1780171
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of infected schoolchildren (Area S)
Study: 1780171
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of individuals excreting >=800 epg (Area W)
Study: 24852468
Drug: High-intensity focused
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity focused ultrasound (HIFU) treatment with total fluence of 150-180 J/cm
Study: 22513659
Drug: 0.6 g
Normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g per kg per day alanyl-glutamine
Study: 12203176
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment program
Study: 8964276
Drug: Carbamazepine 600
Normalized name: carbamazepine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 600 mg (CBZ 600)
Study: 8964276
Drug: Lamotrigine 200
Normalized name: lamotrigine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine 200 mg (LTG 200)
Study: 31332820
Drug: Ilaprazole 30
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 30 mg
Study: 31332820
Drug: Ilaprazole infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ilaprazole infusion
Study: 30554571
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate therapy
Study: 26729895
Drug: lenalidomide plus
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lenalidomide plus low-dose dexamethasone (Rd)
Study: 20808204
Drug: Prednisone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (1.5 mg/kg per day for 2 weeks then 0.75 mg/kg per day for 2 weeks)
Study: 15639724
Drug: First line
Normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line therapy with carboplatin and paclitaxel
Study: 15639724
Drug: Two or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two or more cycles of therapy
Study: 15639724
Drug: Four or
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four or more cycles of therapy
Study: 14592237
Drug: Physiological dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological dose of melatonin (0.14 mg)
Study: 14592237
Drug: Supraphysiological dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraphysiological dose of melatonin (2.2 mg)
Study: 9988788
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (estradiol valerate 2 mg/day)
Study: 9988788
Drug: Cyclic estrogen/sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic estrogen/sequential progestogen regimen
Study: 31000133
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg)
Study: 23149928
Drug: Hydroxybupropion concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxybupropion concentrations (per μg/ml)
Study: 23149928
Drug: Bupropion dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion dosing to achieve hydroxybupropion level of 0.7 μg/ml
Study: 12071235
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (40 mg)
Study: 8909084
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with aftercare orientation and treatment contract
Study: 17242632
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg/d) for 7 days starting 1 week after surgery
Study: 15342900
Drug: Betamethasone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (12 mg, 2 doses, intramuscular injection, 24 hours apart)
Study: 11434939
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% twice daily (BID)
Study: 11434939
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% twice daily (BID)
Study: 32949
Drug: Lorazepam, Hyoscine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam, Hyoscine butylbromide, Ispaghula husk (all three agents)
Study: 32949
Drug: One or
Normalized name: Geone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or two of the potent preparations (Lorazepam, Hyoscine butylbromide, Ispaghula husk)
Study: 19864187
Drug: Implementation intention
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Implementation intention intervention (self‐administered questionnaire)
Study: 24959775
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drugs)
Study: 15369509
Drug: Treatment interruption
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment interruption or poor adherence
Study: 11275026
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy
Study: 25986647
Drug: Buprenorphine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine maintenance treatment (BMT) with 12-step meeting attendance
Study: 20102058
Drug: Niphedipine (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niphedipine (calcium channel blocker)
Study: 14982362
Drug: Mini-implants (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-implants (both miniplates and freestanding miniscrews)
Study: 14982362
Drug: Nonkeratinized mucosa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonkeratinized mucosa surrounding implants
Study: 9284739
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day alendronate (A5)
Study: 9284739
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day alendronate (A10)
Study: 3942084
Drug: Riboflavin supplementation
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin supplementation (0.3 mg/day)
Study: 26186951
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of solifenacin 5 mg and trospium 5 mg with tamsulosin 0.4 mg for 2 months
Study: 26186951
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg only
Study: 22192849
Drug: Liquid, aluminum-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid, aluminum-adjuvanted V710 (30 μg)
Study: 22192849
Drug: Liquid, non-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid, non-adjuvanted V710 (30 μg)
Study: 22192849
Drug: Non-adjuvanted lyophilized
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted lyophilized V710 (60 μg)
Study: 9477005
Drug: Midazolam (6.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (6.1 mg)
Study: 8688987
Drug: Chlorphenamine (CPA)
Normalized name: chlorphenoxamine
DrugBank: Chlorphenoxamine (DB09007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorphenamine (CPA) regular release tablet (Histop) 4 mg
Study: 2203322
Drug: Placebo (cellulose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose, twice daily for 16 weeks)
Study: 9860106
Drug: Flunitrazepam 4
Normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 4 mg
Study: 23289920
Drug: Single-dose nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose nitazoxanide (1,000 mg)